Vibrant Therapeutics

Vibrant Therapeutics is a clinical-stage biotechnology company developing intelligent, logic-gated therapeutics designed to selectively activate in the desired disease microenvironment. Founded in 2019 by Dr. Larry Wang, Ph.D. (co-founder of GenScript), the company leverages an integrated computational and experimental (dry-wet) R&D platform to advance a pipeline of first-in-class and best-in-class programs. Its lead program, VIB305, is a logic-gated, masked T-cell engager (TCE) prodrug targeting EGFR-positive solid tumors, which has received US FDA IND acceptance and is in Phase 1 clinical trials in Australia, China, and the US. The company's proprietary BumbleBee, LogicBee, and NeuroBee platforms combine advanced computing with multi-specific antibody engineering to design safer, more effective biotherapeutics for oncological, autoimmune, and neurological diseases. Vibrant has raised over $100 million in total funding, including a $61 million round backed by Pfizer Ventures and Apricot Capital, and is headquartered in Guangzhou, China with a US presence in Cambridge, Massachusetts.